Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer
10.3349/ymj.2019.60.8.720
- Author:
Ye LI
1
;
Huihui SUN
;
Jie GUAN
;
Tingting JI
;
Xinwei WANG
Author Information
1. Department of Gastroenterology, The 5th People's Hospital of Ji'nan, Jinan, Shandong, China.
- Publication Type:Original Article
- Keywords:
Gastric cancer;
serum microRNA-381;
early diagnosis;
tumor markers
- MeSH:
Area Under Curve;
Biomarkers, Tumor;
Carcinoembryonic Antigen;
Diagnosis;
Down-Regulation;
Early Diagnosis;
Humans;
Kaplan-Meier Estimate;
Lymph Nodes;
Neoplasm Metastasis;
Polymerase Chain Reaction;
ROC Curve;
Sensitivity and Specificity;
Stomach Neoplasms
- From:Yonsei Medical Journal
2019;60(8):720-726
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to explore the potential early diagnostic value of serum microRNA-381(miRNA-381) in patients with gastric cancer (GC). MATERIALS AND METHODS: Patients with advanced gastric cancer (AGC) and early gastric cancer (EGC), as well as healthy individuals, were enrolled in this study. Expression of miRNA-381 in serum was detected using real-time quantitative PCR. Electrochemiluminescence analysis was used to investigate the expression of classic tumor markers, including carbohydrate antigen (CA) 199, CA724, and carcinoembryonic antigen. Finally, receiver operating characteristic curve and Kaplan-Meier analysis were used to determine the value of miRNA-381 in clinical diagnosis of GC. RESULTS: miRNA-381 was differentially expressed among the study groups. AUC analysis showed that the sensitivity and specificity of serum miRNA-381 in the diagnosis of GC were superior to those of other tumor markers. Furthermore, low levels of miRNA-381 expression were positively correlated with lymph node metastasis and AGC. Finally, Kaplan-Meier survival analysis showed that down-regulation of miRNA-381 was associated with lymph node metastasis and the development of GC. CONCLUSION: miRNA381, which was down-regulated in GC, might be a novel early diagnosis marker for patients with GC.
